Posted October 29, 2019
The FDA announced a public meeting for November 4 of this year. The stated purpose of the meeting is to gather scientific information regarding the use of FMT to treat Clostridium difficile (C. diff) infections that are resistant to standard therapies. This follows the recent death of an immune-compromised patient who received FMT contaminated with drug-resistant E. coli. We fear that the FDA will use this tragedy to turn FMT into a drug, turning an inexpensive treatment into a pharmaceutical money maker. Read more.